Skip to content
Back to ANAB

Anaptysbio, Inc

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
42
Purchases
0
Sales
42
Purchase value
$0.00
Sale value
$9.75M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Hollings RentonDirector
4Rule 10b5-1 plan disclosed
Filed Oct 2, 2026Period of report Oct 1, 20260001187333-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 1, 2026
Common StockF1F25,000$49.8743$249.37K10,995Direct
Filing footnotes · 4
  1. F1The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.435 to $50.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The stock option is fully vested and exercisable.
  4. F4In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 92,320 shares of common stock, which options vest according to their terms.
Open on SEC EDGAR
John P. SchmidDirector
4
Filed Apr 1, 2026Period of report Mar 30, 20260001478916-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 30, 2026
Common StockF112,596$55.7087$701.71K39,671Direct
SaleMar 30, 2026
Common StockF27,527$56.7002$426.78K32,144Direct
SaleMar 30, 2026
Common StockF3522$57.3989$29.96K31,622Direct
Filing footnotes · 3
  1. F1The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.20 to $56.11 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.20 to $57.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.21 to $57.92 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Daniel FagaDirector · President, CEO
4
Filed Mar 27, 2026Period of report Mar 25, 20260001673528-26-000007
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 27, 2026
Common StockF3F4510$56.613$28.87K513,134Direct
SaleMar 27, 2026
Common StockF3F52,570$57.9063$148.82K510,564Direct
SaleMar 27, 2026
Common StockF3F63,662$58.6158$214.65K506,902Direct
SaleMar 27, 2026
Common StockF3F7490$59.6237$29.22K506,412Direct
SaleMar 27, 2026
Common StockF3F8550$60.6264$33.34K505,862Direct
SaleMar 27, 2026
Common StockF3F91,012$62.1525$62.90K504,850Direct
SaleMar 27, 2026
Common StockF3F102,592$63.3503$164.20K502,258Direct
SaleMar 27, 2026
Common StockF3F113,155$64.1909$202.52K499,103Direct
SaleMar 27, 2026
Common StockF3F123,038$65.1982$198.07K496,065Direct
SaleMar 27, 2026
Common StockF3100$65.99$6.60K495,965Direct
Filing footnotes · 12
  1. F1Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 25, 2026.
  2. F10The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.71 to $63.685 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F11The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.71 to $64.64 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F12The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.785 to $65.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F2Each PSU represents a conditional right to receive one share of the Issuer's Common Stock.
  6. F3The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  7. F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.285 to $57.215 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.29 to $58.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  9. F6The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.29 to $59.275 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  10. F7The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.29 to $60.08 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  11. F8The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.405 to $61.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  12. F9The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $62.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Eric J LoumeauCHIEF LEGAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Feb 13, 2026Period of report Feb 11, 20260001239648-26-000007
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 11, 2026
Common StockF110,000$54.00$540.00K12,835Direct
Filing footnotes · 3
  1. F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025.
  2. F2The stock option is fully vested.
  3. F3In addition to the options to purchase a total of 35,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 436,010 shares of common stock, which options vest according to their terms.
Open on SEC EDGAR
Magda MarquetDirector
4
Filed Jan 16, 2026Period of report Jan 15, 20260001631486-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 15, 2026
Common StockF19,290$48.1162$447.00K11,640Direct
SaleJan 15, 2026
Common StockF21,710$48.849$83.53K9,930Direct
Filing footnotes · 4
  1. F1The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.595 to $48.54 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.625 to $48.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The stock option is fully vested.
  4. F4In addition to the options to purchase shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 70,104 shares of common stock, which options vest according to their terms.
Open on SEC EDGAR
Paul F. LizzulChief Medical Officer
4
Filed Jan 9, 2026Period of report Jan 7, 20260001711462-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 8, 2026
Common StockF23,650$44.71$163.19K42,088Direct
Filing footnotes · 3
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  2. F2The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  3. F3The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open on SEC EDGAR
Daniel FagaDirector · President, CEO
4
Filed Jan 9, 2026Period of report Jan 7, 20260001673528-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 8, 2026
Common StockF214,281$44.71$638.50K479,344Direct
Filing footnotes · 3
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  2. F2The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  3. F3The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open on SEC EDGAR
Dennis MulroyCHIEF FINANCIAL OFFICER
4
Filed Jan 9, 2026Period of report Jan 7, 20260001276840-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 8, 2026
Common StockF22,515$44.71$112.45K21,852Direct
Filing footnotes · 3
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  2. F2The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  3. F3The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open on SEC EDGAR
Eric J LoumeauCHIEF LEGAL OFFICER
4
Filed Jan 9, 2026Period of report Jan 7, 20260001239648-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 8, 2026
Common StockF22,210$44.71$98.81K12,835Direct
Filing footnotes · 3
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  2. F2The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  3. F3The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open on SEC EDGAR
Paul F. LizzulChief Medical Officer
4
Filed Jan 8, 2026Period of report Jan 6, 20260001711462-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 7, 2026
Common StockF22,235$45.11$100.82K37,213Direct
Filing footnotes · 5
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  2. F2The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  3. F3The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  4. F4The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  5. F5The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open on SEC EDGAR
Daniel FagaDirector · President, CEO
4
Filed Jan 8, 2026Period of report Jan 6, 20260001673528-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 7, 2026
Common StockF29,202$45.11$415.10K466,787Direct
Filing footnotes · 5
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  2. F2The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  3. F3The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  4. F4The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  5. F5The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open on SEC EDGAR
Dennis MulroyCHIEF FINANCIAL OFFICER
4
Filed Jan 8, 2026Period of report Jan 6, 20260001276840-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 7, 2026
Common StockF21,908$45.11$86.07K17,667Direct
Filing footnotes · 5
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  2. F2The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  3. F3The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  4. F4The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  5. F5The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open on SEC EDGAR
Eric J LoumeauCHIEF LEGAL OFFICER
4
Filed Jan 8, 2026Period of report Jan 6, 20260001239648-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 7, 2026
Common StockF22,017$45.11$90.99K16,779Direct
SaleJan 7, 2026
Common StockF3F45,281$45.3839$239.67K11,498Direct
SaleJan 7, 2026
Common StockF3F51,841$46.1301$84.93K9,657Direct
SaleJan 7, 2026
Common StockF3500$47.23$23.62K9,157Direct
Filing footnotes · 8
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  2. F2The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  3. F3The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025.
  4. F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.87 to $45.835 per share, inclusive. The reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.96 to $46.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. F6The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  7. F7The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  8. F8The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open on SEC EDGAR
Paul F. LizzulChief Medical Officer
4
Filed Jan 6, 2026Period of report Jan 3, 20260001711462-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 5, 2026
Common StockF24,219$43.26$182.51K33,303Direct
Filing footnotes · 3
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  2. F2The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  3. F3The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open on SEC EDGAR
Daniel FagaDirector · President, CEO
4
Filed Jan 6, 2026Period of report Jan 3, 20260001673528-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 5, 2026
Common StockF315,309$43.26$662.27K458,139Direct
Filing footnotes · 4
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  2. F2Reflects the acquisition of 2,305 shares acquired under the Company's ESPP.
  3. F3The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  4. F4The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open on SEC EDGAR
Dennis MulroyCHIEF FINANCIAL OFFICER
4
Filed Jan 6, 2026Period of report Jan 3, 20260001276840-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 5, 2026
Common StockF23,363$43.26$145.48K14,330Direct
Filing footnotes · 3
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  2. F2The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  3. F3The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open on SEC EDGAR
Eric J LoumeauCHIEF LEGAL OFFICER
4
Filed Jan 6, 2026Period of report Jan 3, 20260001239648-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 5, 2026
Common StockF22,983$43.26$129.04K13,251Direct
Filing footnotes · 3
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  2. F2The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  3. F3The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open on SEC EDGAR
J. Anthony WareDirector
4
Filed Dec 23, 2025Period of report Dec 23, 20250001715429-25-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 23, 2025
Common StockF13,900$49.575$193.34K9,630Direct
Filing footnotes · 1
  1. F1In addition to the shares the Reporting Person owns reported in Table I, the Reporting Person also holds additional options to purchase up to an aggregate of 126,085 shares of common stock and 6,030 restricted stock units.
Open on SEC EDGAR
Paul F. LizzulChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Dec 23, 2025Period of report Dec 22, 20250001711462-25-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 22, 2025
Common StockF21,500$50.00$75.00K26,967Direct
Filing footnotes · 4
  1. F1Includes the acquisition of 1,324 shares acquired under the Company's ESPP.
  2. F2The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2025.
  3. F3The stock option is fully vested.
  4. F4In addition to the remaining options to purchase 83,500 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 394,810 shares of common stock, which options vest according to their terms.
Open on SEC EDGAR
Dennis MulroyCHIEF FINANCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Dec 23, 2025Period of report Dec 22, 20250001276840-25-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 22, 2025
Common StockF110,000$50.00$500.00K9,401Direct
Filing footnotes · 3
  1. F1The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 11, 2025.
  2. F2The stock option is fully vested.
  3. F3In addition to the remaining options to purchase 60,600 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 339,440 shares of common stock, which options vest according to their terms.
Open on SEC EDGAR
Eric J LoumeauCHIEF LEGAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Dec 23, 2025Period of report Dec 22, 20250001239648-25-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 22, 2025
Common StockF110,000$51.00$510.00K8,947Direct
Filing footnotes · 3
  1. F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025.
  2. F2The stock option is fully vested.
  3. F3In addition to the options to purchase a total of 43,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 414,810 shares of common stock, which options vest according to their terms.
Open on SEC EDGAR
Eric J LoumeauCHIEF LEGAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Dec 18, 2025Period of report Dec 16, 20250001239648-25-000005
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 18, 2025
Common StockF1141$46.99$6.63K8,947Direct
SaleDec 17, 2025
Common StockF110,000$46.00$460.00K9,088Direct
SaleDec 16, 2025
Common StockF1F28,305$44.6756$371.03K13,283Direct
SaleDec 16, 2025
Common StockF1F34,195$45.2369$189.77K9,088Direct
Filing footnotes · 5
  1. F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.12 to $45.11 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.13 to $45.34 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4The stock option is fully vested.
  5. F5In addition to the options to purchase a total of 53,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 414,810 shares of common stock, which options vest according to their terms.
Open on SEC EDGAR
Dennis MulroyCHIEF FINANCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Dec 18, 2025Period of report Dec 16, 20250001276840-25-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 16, 2025
Common StockF2F39,365$44.6152$417.82K15,761Direct
SaleDec 16, 2025
Common StockF2F46,360$45.2062$287.51K9,401Direct
Filing footnotes · 6
  1. F1Reflects the acquisition of 1,324 shares acquired under the Company's ESPP.
  2. F2The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 11, 2025.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.07 to $45.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.065 to $45.32 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5The stock option is fully vested.
  6. F6In addition to the remaining options to purchase 70,600 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 339,440 shares of common stock, which options vest according to their terms.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.